Download PDF
Thromb Haemost 1988; 59(02): 323-328
DOI: 10.1055/s-0038-1642780
Original Articles
Schattauer GmbH Stuttgart

Differential Inhibition of the Platelet Activation Sequence: Shape Change, Micro- and Macro-Aggregation, by a Stable Prostacyclin Analogue (lloprost)

L G Pedvis
The Dept. of Physiology, McGill University, Montreal, Quebec, Canada
,
T Wong
The Dept. of Physiology, McGill University, Montreal, Quebec, Canada
,
M M Frojmovic
The Dept. of Physiology, McGill University, Montreal, Quebec, Canada
› Author Affiliations
Further Information

Publication History

Received 10 April 1987

Accepted after revision 31 December 1987

Publication Date:
21 May 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The relative sensitivities of adenosine diphosphate (ADP)-induced activation, and of prostaglandin-mediated inhibition, were determined for rates of platelet shape change (SC [Vs]), early platelet recruitment measured by electronic platelet counting (PA [PA3]), and turbidometrically-measured aggregation (TA[Va]). Studies were performed in stirred citrated platelet-richplasma from 9 healthy human donors. The [ADP]1/2, ([ADP]giving half maximal rate) was determined for the sequence of activation steps: unactivated platelets → SC → PA → TA. Distinct ADP sensitivities were obtained from log dose-responsestudies, with a relative dose dependency for rates of change in the order of [ADP]1/2 TA > [ADP]1/2 PA > [ADP]1/2 SC of ~4:3:1.Differential inhibition of the above activation scheme was evalu-ated from log dose-response curves for lloprost (ZK 36374), astable carbacyclin analogue of prostacyclin (PGI2), with greaterpotency than PGI2 for the same platelet receptors. IC50 valuescorresponding to lloprost concentrations causing 50% inhibitionof rates of TA (Va), PA (PA3) and SC (Vs) were found in therelative ratios of 1: ~3: ~5, when measured at a common ADPconcentration for all three parameters, or 1: ~2: ~3 when deter-mined at respective [ADP]1/2 values for each parameter. Thus, about 3-5 times more lloprost is required to respectively inhibitthe rates of shape change (Vs) and early platelet recruitment(PA3), than that needed to inhibit the rate of turbidometrically-measured aggregation (Va).

Keywords

Differential activation and inhibition - Shape change - Microaggregation - Macroaggregation - lloprost (ZK 36374)
 

  • References

  • 1 Frojmovie MM, Milton JG. Human platelet size, shape, and related functions in health and disease. Physiol Rev 1982; 62: 185-261
    CrossrefPubMedGoogle Scholar
  • 2 Feinstein MB, Zavoico GB, Halenda SP. Calcium and cyclic AMP:antagonistic modulators of platelet function. In: The Platelets: Phy-siology and Pharmacology. Longenecker GL. (ed.), pp 237-269 Academic Press; London: 1985
    Google Scholar
  • 3 Nomura H, Nakaniski H, Katsuhiko A, Kikkawa U, Nishizuka Y. Inositol phospholipid turnover in stimulus-response coupling. ProgHemost Thromb 1986; 8: 143-158
    PubMedGoogle Scholar
  • 4 Bushfield M, McNicol A, MacIntyre DE. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandinD2 . Biochem I 1985; 232: 267-271
    PubMedGoogle Scholar
  • 5 Weksler BB. Prostacyclin. Prog Hemost Thromb 1982; 6: 113-138
    PubMedGoogle Scholar
  • 6 Froj movie MM, Milton JG, Duchastel A. Microscopic measurementsof platelet aggregation reveal a low ADP-dependent process distinctfrom turbidometrically measured aggregation. J Lab Clin Med 1983; 101: 964-976
    PubMedGoogle Scholar
  • 7 Milton JG, Froj movie MM. Adrenaline and adenosine-phosphate-induced platelet aggregation require shape change: importance ofpseudopods. J Lab Clin Med 1984; 104: 805-815
    PubMedGoogle Scholar
  • 8 Froj movie MM, Milton JG, Gear AR L. Platelet aggregationmeasured in vitro by particle counting: microscopic and electronicmethods. In: Methods in Enzymology. Hawiger J, Colowick SP, Kaplan NO. (eds.) Academic Press; 1988. (in press)
    Google Scholar
  • 9 Frojmovic MM, Milton JG. Physical, chemical and function changesfollowing platelet activation in normal and “giant” platelets. BloodCells 1983; 9: 359-382
    PubMedGoogle Scholar
  • 10 Holmsen H. Platelet secretion In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) pp 390-403 J B Lippincott Co; Toronto: 1982
    Google Scholar
  • 11 Steen VM, Holmsen H. Inhibition of ADP-induced responses inhuman platelets by agents elevating the cyclic AMP level: comparisonof aggregation and shape change. Thromb Haemostas 1984; 52: 333-335
    PubMedGoogle Scholar
  • 12 Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect ofPGEj on platelet function in vitro and in vivo. Br J Haematol 1970; 19: 559-571
    CrossrefPubMedGoogle Scholar
  • Tang SS, Frojmovic MM. Inhibition of platelet function byantithrombotic agents which selectively inhibit low-Kmcyclic 3’,5’-adenosine monophosphate phosphodiesterase. J Lab Clin Med 1980; 95: 241-257
    PubMedGoogle Scholar
  • 14 Favis GR, Lman CO R W. The action of halofenate on platelet shapechange and prostaglandin synthesis. J Lab Clin Med 1978; 92: 45-52
    PubMedGoogle Scholar
  • 15 SChror K, DArius H, MAtzky R, Ohlendorf R. The antiplatelet andcardiovascular actions of a new carbacyclin derivative (ZK 36374) -equipotent to PGI2in vitro. Arch Pharm 1981; 316: 252-255
    CrossrefPubMedGoogle Scholar
  • 16 Casals-Stenzel J, BUse M, Losert W. Comparison of the vasodepressoraction of ZK 36374, a stable prostacyclin derivative, PGI2and PGEXwith their effect on platelet aggregation and bleeding time in rats. Prostaglandins, Leukotrienes Med 1983; 10: 197-212
    CrossrefPubMedGoogle Scholar
  • 17 Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin Exon human platelet function. J LabClin Med 1987; 109: 184-190
    PubMedGoogle Scholar
  • 18 Tang SS, Frojmovic MM. The effects of pC02and pH on plateletshape change and aggregation for human and rabbit platelet-richplasma. Thromb Res 1977; 10: 135-145
    CrossrefPubMedGoogle Scholar
  • 19 Shillinger E. Report SH401 from Dept, of Biomedical Pharmacology, Schering AG, Berlin, West Germany. 1980
    PubMedGoogle Scholar
  • 20 Milton JG, YUng W, GLushak C, Froj movie MM. Kinetics of ADP-induced human platelet shape change: apparent positive cooperativ-ity. Can J Physiol Pharmacol 1980; 58: 45-52
    CrossrefPubMedGoogle Scholar
  • 21 Milton JG, Frojmovic MM. Turbidometric evaluations of platelet activation: Contributions of measured shape change, volume, andearly aggregation. J Pharmacol Methods 1983; 9: 101-115
    CrossrefPubMedGoogle Scholar
  • 22 Chang HN, Robertson CR. Platelet aggregation by laminar shear andBrownian motion. Ann Biomed Eng 1976; 4: 151-183
    CrossrefPubMedGoogle Scholar
  • 23 Saniabadi AR, Lowe GD O, Belch JJ F, Forbes CD, Prentice CR M, Barbenel JC. The novel effect of a new prostacyclin analogueZK 36374 on the aggregation of human platelets in whole blood. Thromb Haemostas 1983; 50: 718-721
    PubMedGoogle Scholar
  • 24 Adaikan PG, Karim SM M, Lau LC, Tai MY, Kottegoda SR. Inhibition of platelet aggregation and antagonism of vasopressin-induced ECG changes in primates by a carboprostacyclin analogue, ZK 36374. Thromb Res 1984; 33: 333-340
    CrossrefPubMedGoogle Scholar
  • 25 Gorman RR, BUnting S, Miller OV. Modulation of human adenylatecyclase by prostacyclin (PGX). Prostaglandins 1977; 133: 377-388
    PubMedGoogle Scholar
  • 26 Tateson JE, MnOncada S, Vane JR. Effects of prostacyclin (PGX) oncyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-397
    CrossrefPubMedGoogle Scholar
  • 27 Wang TY, Hussey CV, Garancis JC. Effects of dibutyryl cyclicadenosinemonophosphate and prostaglandinE1 on platelet aggrega-tion and shape changes. Am J Clin Pathol 1977; 67: 362-367
    CrossrefPubMedGoogle Scholar
  • 28 Rao GH R, Peller JD, White JG. Measurement of ionized calcium inblood platelets with a new generation indicator. BBRC 1985; 132: 652-657
    PubMedGoogle Scholar
  • 29 Hallam TJ, SAnchez A, Rink TJ. Stimulus-response coupling inhuman platelets. Biochem J 1984; 218: 819-827
    CrossrefPubMedGoogle Scholar
  • 30 Rink TJ, Smith SW, Tsien RY. Cytoplasmic free Ca2+in humanplatelets: Ca2+thresholds and Ca-independent activation for shape-change and secretion. FEBS Lett 1982; 148: 21-26
    CrossrefPubMedGoogle Scholar
  • 31 Lapetina EG. Inositide-dependent and independent mechanisms inplatelet activation. In: Phosphoionositides and Receptor MechanismsAlan R Liss 1986; pp 271-286
    PubMedGoogle Scholar
  • 32 Haslam RJ. Signal transduction in platelet activation. In: Thrombosisand Hemostasis. Verstrarete M, VErmylen J, Lijnen R, Arnout J. (eds) pp 147-174 Leuven University Press; Belgium: 1987
    Google Scholar
  • 33 Ware AJ, Johnson PC, Smith M, Salzman EW. Aequorin detectsincreased cytoplasmic calcium in platelets stimulated with phorbolester or diacylglycerol. BBRC 1985; 133: 98-104
    PubMedGoogle Scholar
  • 34 Pollock WK, Rink TJ, Irvine RF. Liberation of [3H] arachidonic acidand changes in cytosolic free calcium in fura-2-loaded human plateletsstimulated by ionomycin and collagen. Biochem J 1986; 235: 869-877
    CrossrefPubMedGoogle Scholar